Follow Us:
Nimesulide

Nimulid

Nimesulide

Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) used in some countries for the short-term relief of acute pain and inflammation, including musculoskeletal pain and primary dysmenorrhoea. It works by inhibiting cyclooxygenase enzymes, particularly COX-2, thereby reducing prostaglandin production and alleviating pain and inflammation. Nimesulide is available in oral tablets, granules, and other formulations depending on the market. Common side effects include nausea, abdominal discomfort, diarrhoea, and dizziness. A major safety concern is potentially serious liver injury, and it may also increase the risk of gastrointestinal bleeding and kidney problems. Nimesulide is restricted or unavailable in several countries because of its liver safety profile; where authorised, it should be used only for the shortest prescribed duration under medical supervision.

Dosage Form:
Dosage Strength:
CAS No.: 51803-78-2
Status:
Manufacturer:
Group: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Sub Group: Preferential COX-2 inhibitors

Uses of Nimesulide

Nimesulide was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:

  • Osteoarthritis: Relief of joint pain, stiffness and inflammation associated with degenerative joint disease.
  • Rheumatoid Arthritis: Management of pain and inflammation associated with chronic inflammatory joint conditions.
  • Musculoskeletal Disorders: Relief of pain associated with selected muscle, tendon and joint disorders.
  • Acute Pain: Short-term management of certain painful inflammatory conditions.
  • Dysmenorrhea: Relief of menstrual pain with selected medicines.
  • Inflammatory Conditions: Reduction of pain, swelling and inflammation in selected musculoskeletal conditions.

Contraindication of Nimesulide

Nimesulide was historically subject to specific precautions during administration to ensure patient safety. Its former precautions included:

  • Known hypersensitivity to the medicine or previous serious allergic reactions to NSAIDs.
  • Active peptic ulcer, gastrointestinal bleeding or a history of NSAID-associated gastrointestinal perforation.
  • Severe renal or hepatic impairment, where specified in the product information.
  • Severe heart failure or certain established cardiovascular conditions.
  • Active gastrointestinal bleeding or significant bleeding disorders.
  • Perioperative pain management associated with coronary artery bypass graft (CABG) surgery.
  • Pregnancy during the third trimester.
  • Severe liver disease or previous serious liver reactions, particularly with medicines such as nimesulide.

Precautions for Nimesulide

Nimesulide was majorly subjected to specific precautions during administration to ensure patient safety. Its former precautions included:

  • Gastrointestinal Health: Although preferential COX-2 inhibitors may have a lower risk of gastrointestinal injury than some non-selective NSAIDs, ulcers, bleeding and gastrointestinal perforation can still occur.
  • Cardiovascular Risk: Patients with hypertension, heart disease, previous stroke or other cardiovascular risk factors require careful assessment.
  • Kidney Function: Caution is necessary in patients with kidney impairment, dehydration or conditions that reduce renal blood flow.
  • Liver Function: Medicines such as nimesulide require particular attention to liver safety because of the risk of serious hepatic reactions.
  • Blood Pressure: These medicines may cause fluid retention, swelling and increased blood pressure.
  • Pregnancy: NSAIDs should generally be avoided from 20 weeks of pregnancy unless specifically advised by a healthcare professional and avoided from 30 weeks because of fetal risks.
  • Elderly Patients: Older adults may be more susceptible to gastrointestinal bleeding, kidney complications and cardiovascular adverse effects.
  • Duration of Treatment: Use the lowest effective dose for the shortest appropriate duration.

Drug Interactions for Nimesulide

Potential drug interactions were historically documented when Nimesulide was prescribed alongside certain medications. These included:

  • Anticoagulants: Warfarin and direct oral anticoagulants may increase the risk of bleeding when combined with NSAIDs.
  • Antiplatelet Drugs: Aspirin and clopidogrel may increase gastrointestinal bleeding risk.
  • Corticosteroids: Concurrent use may increase the risk of gastrointestinal ulcers and bleeding.
  • Other NSAIDs: Combining multiple NSAIDs may increase gastrointestinal, cardiovascular and kidney-related adverse effects.
  • ACE Inhibitors and ARBs: Medicines such as ramipril, enalapril and losartan may have reduced blood-pressure-lowering effects and increased renal risks when combined with NSAIDs.
  • Diuretics: Furosemide and hydrochlorothiazide may have reduced effectiveness, with a potential increase in kidney-related complications.
  • Lithium: NSAIDs may increase lithium concentrations and the risk of toxicity.
  • Methotrexate: Concurrent use may increase methotrexate exposure and toxicity, particularly in patients with impaired renal function.
  • Ciclosporin and Tacrolimus: Combined use may increase the risk of kidney damage.

Frequently Asked Questions

The most frequently asked questions focus on import, export, documentations, and regulation for Nimesulide.

The Nimesulide is a pharmaceutical active pharmaceutical ingredient (API) used in manufacturing of Nimesulide.

: Provides active pharmaceutical ingredients (APIs), customized production, and OEM/ODM services with research and technical cooperation across Europe, the USA, and India via Primeera Healthcare.

  • Therapeutic Goods Administration (TGA):
  • US Food and Drug Administration (USFDA):
  • European Medicines Agency (EMA):
  • African Medicines Agency (AMA):
  • National Medical Products Administration (NMPA):
  • Central Drugs Standard Control Organization (CDSCO):

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Nimesulide, subject to confirmation of its current regulatory status and eligibility for import into India.

Documentation Required for Nimesulide Import

The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.

Import Regulations and dcoumentation for Nimesulide

  • Import Documentation Assistance:
    Support with organising commercial invoices, packing lists, manufacturer details, product specifications, certificates of analysis, and other relevant documents required for regulatory review and customs processing.

  • Regulatory Coordination:
    Assistance with identifying applicable CDSCO requirements, import authorisations, and documentation procedures, subject to the product's regulatory status and the proposed import route.
  • Shipping and Customs Coordination:
    Coordination with relevant logistics providers and customs professionals to organise shipment documentation and facilitate clearance where legally permitted.
  • Compliance Verification:
    Preliminary review of available product and shipment documentation to identify potential regulatory gaps before procurement or dispatch. Import arrangements will proceed only after the applicable permissions and restrictions have been verified.

Customs Clearance and Compliance Handling of Nimesulide Import

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Nimesulide, subject to confirmation of its current regulatory status and eligibility for import into India.

Export Regulations and dcoumentation for Nimesulide

The export of Nimesulide from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.

Documentation Required for Nimesulide Emport

  • Export Documentation Assistance:
    Assistance with organising commercial invoices, packing lists, manufacturer details, Nimesulide specifications, certificates of analysis, and other supporting documents required for Nimesulide export and customs processing.
  • Regulatory Coordination:
    Support in identifying applicable country specific Nimesulide export requirements, relevant manufacturing and export authorisations, and destination-country registration or import approval requirements, subject to the Nimesulide regulatory status.
  • Shipping and Customs Coordination:
    Coordination with logistics providers, freight forwarders, and customs professionals to organise shipping documentation, export declarations, and customs clearance procedures where legally permitted.
  • Compliance Verification:
    Preliminary review of available Nimesulide documentation, labelling, Nimesulide manufacturing information, and destination-market requirements to identify potential regulatory gaps before dispatch. Export arrangements will proceed only after the applicable restrictions and authorisations have been verified.

Customs Clearance and Compliance Handling of Nimesulide Export

Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Nimesulide, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.

Product Export Support

If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.